Partners

FibroFind_logo_cmyk_strapline

FibroFind Bio

Expertise Partner

FibroFind is a rapidly developing biomedical sciences company with a deep understanding of fibrosis biology that has employed this knowledge to design bespoke human tissue assays.  Our proprietary bioreactor cultured precision-cut tissue slices (PCTS) offer superior performance for biomarker identification, toxicology, target discovery and drug efficacy evaluation.  Harnessing the power of robotics, AI-guided automated data analysis and a highly skilled technical team, FibroFind delivers unmatched technical quality in studies.  Our current portfolio includes healthy and IPF-lung PCTS in 24, and 96 well formats, allowing us to tailor studies to best meet your investigative requirements.

www.fibrofind.com

vitalograph logo

Vitalograph

Hosting Partner

Vitalograph provides sponsors with everything needed to collect, QC, and report on Respiratory endpoint data for the following assessments: FEV1, FVC, SVC, PEF, ECG, ePRO/ eCOA, FeNO, DLCO, 6MWT, and objective cough counting. Our knowledgeable and responsive teams of dedicated project and data managers, clinical respiratory physiologists, cough analysts, software development engineers, in-house QA and logistic specialists, plus highly experienced site support staff, are what make our innovative and personalized solutions possible.

www.vitalograph.com

Brainomix Logo

Brainomix

Program Partner

Brainomix specializes in the creation of clinically available AI powered software solutions to enable precision medicine for better treatment decisions. With origins as a spin-out from the University of Oxford, Brainomix developed the world's first AI-powered software for stroke assessment and is now an expanding commercial-stage company with offices in the UK, Ireland and the USA. Brainomix has operations in more than 30 territories, including a number of competitively awarded country-wide deployments to achieve complete national coverage with it's AI software. Brainomix's e-Lung technology and suite of AI-powered quantitative imaging biomarkers are currently utilised by sponsors to support the development and commercialisation of treatments for interstitial lung disease, both during clinical research and in real-world clinical practice.

www.brainomix.com

 

Mannkind_Logo_RGB (1)

Mannkind

Industry Partner

MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, IPF, PAH and NTM lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

www.mannkindcorp.com

fortrea_logo

Fortrea

Innovation Partner

Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

www.fortrea.com

 

strados

Strados

Exhibition Partner

www.stradoslabs.com

Ionis_Logo_RGB (002)

Ionis

Industry Partner

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

Ionispharma.com

 

partner pros

FIND OUT MORE ABOUT OUR PARTNERSHIP OPPORTUNITIES